Merck KGaA To Build Biopharmaceutical Plant

Confirming its commitment to the growing biotechnology sector, German firm Merck KGaA has decided to construct a biopharmaceutical production plant at its headquarters in Darmstadt, Germany. At an estimated cost of EUR190mn (US$244mn), the facility represents the second-largest single investment ever made by the company. Approximately 190 highly skilled employees will be recruited to operate the plant and construction is expected to commence in

To read the full article, please choose one of the following options: